QUALITY ADJUSTED SURVIVAL ANALYSIS

被引:223
作者
GLASZIOU, PP
SIMES, RJ
GELBER, RD
机构
[1] Department of Public Health, University of Sydney, Sydney
[2] NHMRC Clinical Trials Centre, University of Sydney, Sydney
[3] Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts
关键词
D O I
10.1002/sim.4780091106
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
We present a technique, quality adjusted survival analysis, for the analysis of controlled trials where patients may experience several health states which differ in their quality of life. When the data are censored, a survival analysis of the quality adjusted life years achieved may involve informative censoring, and produce biased estimates. To overcome this, we partition the survival curve; the resulting areas, which represent the mean time in each state, are multiplied by utility weights to provide an unbiased estimate of (restricted) quality adjusted survival. If the appropriate weights are in doubt, the results are best presented as a threshold analysis over the utility weights, allowing individual recommendation to be read from a simple graph. The certainty of the conclusions can be presented as confidence bands on the threshold line. The techniques are illustrated with a re‐analysis of a large three‐arm trial of adjuvant chemoendocrine therapy for stage II breast cancer in post‐menopausal women. This shows that if the value of time spent in toxicity is greater than the time spent in relapse, we can be 95 per cent confident that chemoendocrine therapy is the preferred option. Copyright © 1990 John Wiley & Sons, Ltd.
引用
收藏
页码:1259 / 1276
页数:18
相关论文
共 19 条
  • [1] Schwartz D., Flamant R., Lellouch J., Clinical Trials, (1980)
  • [2] Simes J., Application of statistical decision theory to treatment choices: implications for the design and analysis of clinical trials, Statistics in Medicine, 5, pp. 411-420, (1986)
  • [3] Hilden J., Reporting clinical trials from the viewpoint of a patient's choice of treatment, Statistics in Medicine, 6, pp. 745-752, (1987)
  • [4] Torrance G.W., Health status index models: a unified mathematical view, Management Science, 22, pp. 990-1001, (1976)
  • [5] Torrance G.W., Utility approach to measuring health‐related quality of life, Journal of Chronic Diseases, 40, pp. 593-600, (1987)
  • [6] Chemotherapy of advanced ovarian carcinoma: a randomized comparison of combination versus sequential therapy using chlorambucil and cisplatin, Gynecologic Oncology, 23, pp. 1-13, (1986)
  • [7] Randomized trial of chemoendocrine therapy, endocrine therapy, and mastectomy alone in postmenopausal patients with operable breast cancer and axillary metastasis, Lancet, 1, pp. 1256-1260, (1984)
  • [8] Goldhirsch A., Gelber R.D., Simes R.J., Glasziou P.P., Coates A., Costs and benefits of adjuvant therapy in breast cancer: a quality adjusted survival analysis, Journal of Clinical Oncology, 7, pp. 36-44, (1989)
  • [9] Weinstein M.C., Fineberg H., Clinical Decision Analysis, (1980)
  • [10] Keeney R.L., Raiffa H., Decisions with Multiple Objectives: Preference and Value Tradeoffs, (1976)